BTIG raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps a Buy rating on the shares after its Q4 earnings beat and “solid guide”. Guardant had an excellent 2024 and investor sentiment has significantly shifted positive as the company has a number of key catalysts ahead here in 2025, the analyst tells investors in a research note. The firm has long thought that Shield is underappreciated, but now also believes that Reveal and its flagship G360 franchise are underappreciated as well, BTIG adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $56 from $49 at Guggenheim
- Guardant Health’s Promising Growth Prospects: Buy Rating Backed by Strong Revenue Guidance and Optimistic Projections
- Guardant Health’s Strong 2024 Growth and 2025 Outlook
- Guardant Health: Strong Buy Rating Driven by Surpassing Performance and Optimistic Growth Outlook
- Guardant Health options imply 9.3% move in share price post-earnings